Back to your search result

Description

A cell-permeable, bioavailable, non-toxic thiadiazolopyrimidinone based compound that acts a potent, reversible and ATP-competitive dual inhibitor of CK2 & SRPK1 (IC50 = 0.2 & 2.4 µ,M, respectively). Displays excellent selectivity in a 306-kinase panel (% inhibition at 10 µ,M = 82.5, 70.9, 59.9 & 13.7 for CK2alpha1/beta, CK2alpha2/beta, SRPK1 & SRPK2, respectively). Synergistically suppresses VEGF production in a time and dose-dependent manner and down-regulates several angiogenesis genes expression (10 µ,M in ARPE-19 cells). Shown to be highly efficacious than SRPIN340 (Cat. No. 504293) and significantly inhibit choroidal neovascularization in a mouse model of age-related macular degeneration (intravitreous injection or topical administration). Please note that the molecular weight for this compound is batch-specific due to variable water content. Please refer to the vial label or the certificate of analysis for the batch-specific molecular weight. The molecular weight provided represents the baseline molecular weight without water., A cell-permeable, bioavailable, non-toxic thiadiazolopyrimidinone based compound that acts a potent, reversible and ATP-competitive dual inhibitor of CK2 & SRPK1 (IC50 = 0.2 & 2.4 µ,M, respectively). Displays excellent selectivity in a 306-kinase panel (% inhibition at 10 µ,M = 82.5, 70.9, 59.9 & 13.7 for CK2alpha1/beta, CK2alpha2/beta, SRPK1 & SRPK2, respectively). Synergistically suppresses VEGF production in a time and dose-dependent manner and down-regulates several angiogenesis genes expression (10 µ,M in ARPE-19 cells). Shown to be highly efficacious than SRPIN340 (Cat. No. 504293) and significantly inhibit choroidal neovascularization in a mouse model of age-related macular degeneration (intravitreous injection or topical administration).